Progress of Immunocyte in Idiopathic Pulmonary Fibrosis

Idiopathic pulmonary fibrosis (IPF) belongs to chronic progressive interstitial lung disease. The morbility of IPF is increasing with poor prognosis and high mortality year by year. At present, Nintedanib and Pirfenidone have been only recommended by guideline, however both are limited in clinical application because of their high price. The pathogenesis of IPF is not entirely clear. However, immune cells and their interactions play an important role in the pathogenesis of IPF. In this review, it is summarized the function mechanism of immune cells and related medicines of IPF in order to provid basis for further exploration of immunotherapy.